Table 2 Cardiorenal effects of SGLT-2i in primary and secondary prevention in T2D
SGLT-2 inhibitors | EMPA-REGa | CANVAS | DECLARE | VERTIS-CVa | SCORED |
|---|---|---|---|---|---|
MACE | |||||
Primary | – | Neutral | Neutral | – | Reduced |
Secondary | Reduced | Reduced | Neutral | Neutral | Reduced |
Heart failure | |||||
Primary | – | Reduced | Reduced | – | Reduced |
Secondary | Reduced | Reduced | Reduced | Reduced | Reduced |
DKD | |||||
Primary | – | Reduced | Reduced | – | Neutral |
Secondary | Reduced | Reduced | Reduced | Neutral | Neutral |